The idea that NRAS-driven melanoma might be more sensitive to immunotherapy may relate to the slightly higher average number of mutations in these tumors compared to BRAF-driven tumors (Akbani et al., 2015; Krauthammer et al., 2012). This evidence concerns the gene BRAF and melanoma.